Nectar Lifesciences Performance dei guadagni passati
Il passato criteri di controllo 2/6
Nectar Lifesciences's earnings have been declining at an average annual rate of -20.7%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 11.4% per year. Nectar Lifesciences's return on equity is 0.6%, and it has net margins of 0.4%.
Informazioni chiave
-20.7%
Tasso di crescita degli utili
-20.7%
Tasso di crescita dell'EPS
Pharmaceuticals Crescita del settore | 17.5% |
Tasso di crescita dei ricavi | -11.4% |
Rendimento del capitale proprio | 0.6% |
Margine netto | 0.4% |
Prossimo aggiornamento sui guadagni | 14 Nov 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Revenues Working Against Nectar Lifesciences Limited's (NSE:NECLIFE) Share Price Following 26% Dive
Oct 11Nectar Lifesciences Limited (NSE:NECLIFE) Shares Fly 31% But Investors Aren't Buying For Growth
Aug 22Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden
Jul 27Nectar Lifesciences Limited (NSE:NECLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Feb 19Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?
Dec 22Nectar Lifesciences (NSE:NECLIFE) Has Debt But No Earnings; Should You Worry?
Jun 16Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt
Jun 21Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt
Jul 29Is Nectar Lifesciences Limited (NSE:NECLIFE) A Risky Dividend Stock?
Feb 25Nectar Lifesciences (NSE:NECLIFE) Has A Somewhat Strained Balance Sheet
Jan 21Zooming in on NSE:NECLIFE's 0.3% Dividend Yield
Nov 02Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?
Sep 07If You Had Bought Nectar Lifesciences (NSE:NECLIFE) Stock A Year Ago, You Could Pocket A 47% Gain Today
Aug 09The Nectar Lifesciences (NSE:NECLIFE) Share Price Has Gained 47% And Shareholders Are Hoping For More
Aug 09What You Can Learn From Nectar Lifesciences Limited's (NSE:NECLIFE) P/E
Jul 13Ripartizione dei ricavi e delle spese
Come Nectar Lifesciences guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
---|---|---|---|---|
30 Jun 24 | 16,493 | 61 | 918 | 0 |
31 Mar 24 | 16,846 | 50 | 866 | 0 |
31 Dec 23 | 16,322 | 81 | 829 | 0 |
30 Sep 23 | 15,241 | -28 | 810 | 0 |
30 Jun 23 | 15,148 | -263 | 797 | 0 |
31 Mar 23 | 15,237 | -242 | 796 | 0 |
31 Dec 22 | 16,120 | -162 | 789 | 0 |
30 Sep 22 | 17,109 | 28 | 785 | 0 |
30 Jun 22 | 16,868 | 272 | 749 | 0 |
31 Mar 22 | 16,689 | 250 | 763 | 0 |
31 Dec 21 | 15,421 | -276 | 857 | 0 |
30 Sep 21 | 14,765 | -454 | 868 | 0 |
30 Jun 21 | 15,387 | -546 | 742 | 0 |
31 Mar 21 | 15,433 | -733 | 872 | 0 |
31 Dec 20 | 17,586 | -249 | 765 | 0 |
30 Sep 20 | 20,291 | -86 | 776 | 0 |
30 Jun 20 | 21,807 | 12 | 804 | 0 |
31 Mar 20 | 23,664 | 318 | 828 | 0 |
31 Dec 19 | 25,973 | 419 | 814 | 0 |
30 Sep 19 | 26,819 | 446 | 809 | 0 |
30 Jun 19 | 28,274 | 480 | 798 | 0 |
31 Mar 19 | 27,829 | 476 | 812 | 0 |
31 Mar 18 | 18,763 | 523 | 798 | 0 |
31 Mar 17 | 16,437 | 553 | 806 | 0 |
31 Mar 16 | 16,757 | 542 | 832 | 0 |
31 Mar 15 | 16,436 | 663 | 639 | 0 |
31 Mar 14 | 16,383 | 621 | 938 | 0 |
Guadagni di qualità: NECLIFE has high quality earnings.
Margine di profitto in crescita: NECLIFE became profitable in the past.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: NECLIFE's earnings have declined by 20.7% per year over the past 5 years.
Accelerare la crescita: NECLIFE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Guadagni vs Settore: NECLIFE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.1%).
Rendimento del capitale proprio
ROE elevato: NECLIFE's Return on Equity (0.6%) is considered low.